Sulodexide – indications for use Review article
Article Sidebar
Published:
Sep 30, 2019
Keywords:
sulodexide, indications, chronic venous insufficiency, arterial insufficiency, venous thromboembolism, prevention
Main Article Content
Abstract
Chemical structure of sulodexide is a similar to heparin. This drug has anticoagulant, profibrinolytic, anti-inflammatory and protective effects on the vascular endothelium. It is used to treat venous and arterial thromboembolism. Improves healing of leg ulcers in patients with venous and arterial insufficiency. It also reduces the risk of recurrence of thrombosis in prolonged secondary prevention of venous thromboembolism.
Article Details
How to Cite
Okopień, B., Maligłówka, M., & Anton, M. (2019). Sulodexide – indications for use. Medycyna Faktow (J EBM), 12(3(44), 246-249. https://doi.org/10.24292/01.MF.0319.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Pisano L., Moronesi F., Falco F. et al.: The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. Thromb. Res. 1986; 41(1): 23-31.
2. Elmi G., Di Pasquale G., Pesavento R.: The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism – still a challenging issue. Vasa 2017; 46(2): 87-95.
3. Vessel Due F – charakterystyka produktu leczniczego.
4. Carroll B.J., Piazza G., Goldhaber S.Z.: Sulodexide in venous disease. J. Thromb. Haemost. 2019; 17(1): 31-38.
5. Raffetto J.D.: Pathophysiology of Chronic Venous Disease and Venous Ulcers. Surg. Clin. North Am. 2018; 98(2): 337-347.
6. Becker B.F., Jacob M., Leipert S. et al.: Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br. J. Clin. Pharmacol. 2015; 80(3): 389-402.
7. Cospite M., Ferrara F., Cospite V., Palazzini E.: Sulodexide and the microcirculatory component in microphlebopathies. Curr. Med. Res. Opin. 1992; 13(1): 56-60.
8. Elleuch N., Zidi H., Bellamine Z. et al.: Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther. 2016; 33(9): 1536-1549.
9. Patton L.R.: Are community leg ulcer clinics more cost-effective than home care visits? J. Wound Care. 2009; 18(2): 49-50, 52.
10. Serra R., Buffone G., Costanzo G. et al.: Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann. Vasc. Surg. 2013; 27(3): 329-331.
11. Wu B., Lu J., Yang M., Xu T.: Sulodexide for treating venous leg ulcers. Cochrane Wounds Group, editor. Cochrane Database Syst. Rev. [Internet]. 2016 Jun 2 [cited 2019 Mar 27] [online].
12. Serra R., Gallelli L., Conti A. et al.: The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des. Devel. Ther. 2014: 519.
13. Giannotti G., Landmesser U.: Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007; 32(7): 568-572.
14. Sosińska P., Baum E., Maćkowiak B. et al.: Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells. Cell Physiol. Biochem. 2016; 40(5): 1005-1012.
15. Sosińska-Zawierucha P., Maćkowiak B., Staniszewski R. et al.: Sulodexide Slows Down the Senescence of Aortic Endothelial Cells Exposed to Serum from Patients with Peripheral Artery Diseases. Cell Physiol. Biochem. 2018; 45(6): 2225-2232.
16. Cosmi B.: Management of idiopathic venous thromboembolism. Expert Rev. Cardiovasc. Ther. 2016; 14(12): 1371-1384.
17. Andreozzi G.M., Bignamini A.A., Davì G. et al.: Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 2015; 132(20): 1891-1897.
18. Broekhuizen L.N., Lemkes B.A., Mooij H.L. et al.: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53(12): 2646-2655.
19. Olde Engberink R.H.G., Heerspink H.J.L., de Zeeuw D., Vogt L.: Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies: Sulodexide lowers BP in diabetic nephropathy. Br. J. Clin. Pharmacol. 2016; 82(5): 1351-1357.
20. Olde Engberink R.H.G., Rorije N.M.G, Lambers Heerspink H.J. et al.: The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis: Sulodexide and blood pressure. Br. J. Clin. Pharmacol. 2015; 80(6): 1245-1253.
2. Elmi G., Di Pasquale G., Pesavento R.: The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism – still a challenging issue. Vasa 2017; 46(2): 87-95.
3. Vessel Due F – charakterystyka produktu leczniczego.
4. Carroll B.J., Piazza G., Goldhaber S.Z.: Sulodexide in venous disease. J. Thromb. Haemost. 2019; 17(1): 31-38.
5. Raffetto J.D.: Pathophysiology of Chronic Venous Disease and Venous Ulcers. Surg. Clin. North Am. 2018; 98(2): 337-347.
6. Becker B.F., Jacob M., Leipert S. et al.: Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases. Br. J. Clin. Pharmacol. 2015; 80(3): 389-402.
7. Cospite M., Ferrara F., Cospite V., Palazzini E.: Sulodexide and the microcirculatory component in microphlebopathies. Curr. Med. Res. Opin. 1992; 13(1): 56-60.
8. Elleuch N., Zidi H., Bellamine Z. et al.: Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther. 2016; 33(9): 1536-1549.
9. Patton L.R.: Are community leg ulcer clinics more cost-effective than home care visits? J. Wound Care. 2009; 18(2): 49-50, 52.
10. Serra R., Buffone G., Costanzo G. et al.: Varicocele in younger as risk factor for inguinal hernia and for chronic venous disease in older: preliminary results of a prospective cohort study. Ann. Vasc. Surg. 2013; 27(3): 329-331.
11. Wu B., Lu J., Yang M., Xu T.: Sulodexide for treating venous leg ulcers. Cochrane Wounds Group, editor. Cochrane Database Syst. Rev. [Internet]. 2016 Jun 2 [cited 2019 Mar 27] [online].
12. Serra R., Gallelli L., Conti A. et al.: The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des. Devel. Ther. 2014: 519.
13. Giannotti G., Landmesser U.: Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007; 32(7): 568-572.
14. Sosińska P., Baum E., Maćkowiak B. et al.: Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells. Cell Physiol. Biochem. 2016; 40(5): 1005-1012.
15. Sosińska-Zawierucha P., Maćkowiak B., Staniszewski R. et al.: Sulodexide Slows Down the Senescence of Aortic Endothelial Cells Exposed to Serum from Patients with Peripheral Artery Diseases. Cell Physiol. Biochem. 2018; 45(6): 2225-2232.
16. Cosmi B.: Management of idiopathic venous thromboembolism. Expert Rev. Cardiovasc. Ther. 2016; 14(12): 1371-1384.
17. Andreozzi G.M., Bignamini A.A., Davì G. et al.: Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 2015; 132(20): 1891-1897.
18. Broekhuizen L.N., Lemkes B.A., Mooij H.L. et al.: Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53(12): 2646-2655.
19. Olde Engberink R.H.G., Heerspink H.J.L., de Zeeuw D., Vogt L.: Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies: Sulodexide lowers BP in diabetic nephropathy. Br. J. Clin. Pharmacol. 2016; 82(5): 1351-1357.
20. Olde Engberink R.H.G., Rorije N.M.G, Lambers Heerspink H.J. et al.: The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis: Sulodexide and blood pressure. Br. J. Clin. Pharmacol. 2015; 80(6): 1245-1253.